CH Biotech R&D Co., Ltd. (TPE:6534)
Taiwan
· Delayed Price · Currency is TWD 93.40
-2.50 (-2.61%)
Apr 29, 2026, 1:30 PM CST
CH Biotech R&D Revenue
In the year 2025, CH Biotech R&D had annual revenue of 1.82B TWD with 11.21% growth. CH Biotech R&D had revenue of 328.38M in the quarter ending December 31, 2025, with 19.24% growth.
Revenue
1.82B
Revenue Growth
+11.21%
P/S Ratio
5.28
Revenue / Employee
n/a
Employees
n/a
Market Cap
9.60B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.82B | 183.45M | 11.21% |
| Dec 31, 2024 | 1.64B | 120.91M | 7.98% |
| Dec 31, 2023 | 1.51B | 80.71M | 5.63% |
| Dec 31, 2022 | 1.43B | 415.61M | 40.81% |
| Dec 31, 2021 | 1.02B | 316.32M | 45.05% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Nan Ya Plastics | 259.91B |
| Formosa Plastics | 175.41B |
| Formosa Chemicals & Fibre | 287.03B |
| China Steel | 317.16B |
| International CSRC Investment Holdings | 15.33B |
| Sesoda | 6.16B |
| Coremax | 6.19B |
| Tang Eng Iron Works | 9.55B |